Get started
Author

Barbara Goodnature

Observed names: Barbara A Goodnature, Barbara A. Goodnature
Institution: Mayo Clinic
Observed institution: Mayo Clinic
ORCID: 0009-0009-1508-6242
Observed ORCID: 0009-0009-1508-6242
OpenAlex ID: A5078024108
Evaluation of vertebroplasty with a validated outcome measure: the Roland-Morris Disability Questionnaire.
2006 · Andrew T Trout, David F Kallmes, et al. · PubMed · 68
Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action
2020 · Junmei Cairns, James N. Ingle, et al. · JCI Insight · 42
PDF
Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
2020 · James N. Ingle, Junmei Cairns, et al. · Clinical Cancer Research · 38
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
2021 · Junmei Cairns, Krishna R. Kalari, et al. · Clinical Pharmacology & Therapeutics · 7
PDF
Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al. · Clinical Cancer Research · 4
Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer
2020 · James N. Ingle, Krishna R. Kalari, et al. · Pharmacogenetics and Genomics · 4
Abstract OT1-04-02: Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early stage breast cancer: A prospective trial
2023 · Tufia C. Haddad, Vera Suman, et al. · Cancer Research · 2
Data from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al. · 1
Supplementary Data Clean from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
2023 · James N. Ingle, Junmei Cairns, et al. · 1
Supplemental Table 3 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Supplemental Table 3 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Data from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Supplemental Table 1 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Supplemental Table 1 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
2024 · Tufia C. Haddad, Vera J. Suman, et al.
Data from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
2023 · James N. Ingle, Junmei Cairns, et al.
Data from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
2023 · James N. Ingle, Junmei Cairns, et al.
Supplementary Data Clean from Anastrozole has an Association between Degree of Estrogen Suppression and Outcomes in Early Breast Cancer and is a Ligand for Estrogen Receptor α
2023 · James N. Ingle, Junmei Cairns, et al.
Works count: 19
Citation count: 167
H-index: 4
I10-index: 3
Year
Topic
Type